Saeed Yafei1, Fathy Elsewy2, Eman Youssef3, Mohammed Ayman4, Mohamed El-Shafei5. 1. Diabetes & Metabolism Unit, Internal Medicine Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt; Internal Medicine Department, Faculty of Medicine and Health Sciences, Taiz University, Taiz, Yemen. Electronic address: saeedyafei@gmail.com. 2. Diabetes & Metabolism Unit, Internal Medicine Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt. Electronic address: fathysewy1955@hotmail.com. 3. Diabetes & Metabolism Unit, Internal Medicine Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt. Electronic address: dr.emanyoussef@gmail.com. 4. Cardiology and Angiology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt. Electronic address: aymanabdelhay@gmail.com. 5. Radiodiagnosis Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt. Electronic address: mohamedelshafei@yahoo.com.
Abstract
AIM: To evaluate the association of serum FGF21 with subclinical atherosclerosis and pulse wave velocity, a marker of arterial stiffness, in type 2 diabetes Egyptian patients. PATIENTS AND METHODS: Fasting serum FGF21 was measured in 120 type 2 diabetes patients without clinical atherosclerotic cardiovascular disease (mean age 51.1 ± 7.7 years; 63.3 women). In addition to basic laboratory tests, serum adiponectin and ultrasonographic examination of CIMT, ankle brachial index (ABI) and carotid-femoral pulse wave velocity (cfPWV) were performed. RESULTS: Patients with subclinical atherosclerosis have higher serum FGF21 than those without (218 ± 66.8 pg/mL Vs 170 ± 43.1 pg/mL, P < 0.001). FGF21 correlated positively with CIMT and cfPWV (P < 0.001) regardless of patient gender. In logistic regression analysis, circulating FGF21 was found to be an independent predictor for subclinical atherosclerosis (P = 0.023) in addition to dyslipidemia, hypertension and adiponectin. FGF21 was also found to be an independent determinant of cfPWV in stepwise multiple regression analysis. ROC curve analysis was done and cutoff high risk FGF21 level of 184 pg/mL for the prediction of subclinical atherosclerosis with a sensitivity and specificity of 66.7%. CONCLUSIONS: Serum FGF21 levels correlated with carotid intima media thickness and predict subclinical atherosclerosis. Serum FGF21 is also correlated positively with cfPWV and arterial stiffness in type 2 diabetes patients.
AIM: To evaluate the association of serum FGF21 with subclinical atherosclerosis and pulse wave velocity, a marker of arterial stiffness, in type 2 diabetes Egyptian patients. PATIENTS AND METHODS: Fasting serum FGF21 was measured in 120 type 2 diabetespatients without clinical atherosclerotic cardiovascular disease (mean age 51.1 ± 7.7 years; 63.3 women). In addition to basic laboratory tests, serum adiponectin and ultrasonographic examination of CIMT, ankle brachial index (ABI) and carotid-femoral pulse wave velocity (cfPWV) were performed. RESULTS:Patients with subclinical atherosclerosis have higher serum FGF21 than those without (218 ± 66.8 pg/mL Vs 170 ± 43.1 pg/mL, P < 0.001). FGF21 correlated positively with CIMT and cfPWV (P < 0.001) regardless of patient gender. In logistic regression analysis, circulating FGF21 was found to be an independent predictor for subclinical atherosclerosis (P = 0.023) in addition to dyslipidemia, hypertension and adiponectin. FGF21 was also found to be an independent determinant of cfPWV in stepwise multiple regression analysis. ROC curve analysis was done and cutoff high risk FGF21 level of 184 pg/mL for the prediction of subclinical atherosclerosis with a sensitivity and specificity of 66.7%. CONCLUSIONS: Serum FGF21 levels correlated with carotid intima media thickness and predict subclinical atherosclerosis. Serum FGF21 is also correlated positively with cfPWV and arterial stiffness in type 2 diabetespatients.
Authors: Lin Xiaolong; Guo Dongmin; Mihua Liu; Wang Zuo; Hu Huijun; Tan Qiufen; Hu XueMei; Lin Wensheng; Pan Yuping; Lin Jun; Zeng Zhaolin Journal: J Cell Mol Med Date: 2020-03-30 Impact factor: 5.310
Authors: Shuen Yee Lee; Stephen F Burns; Kenneth K C Ng; David J Stensel; Liang Zhong; Frankie H Y Tan; Kar Ling Chia; Kai Deng Fam; Margaret M C Yap; Kwee Poo Yeo; Eric P H Yap; Chin Leong Lim Journal: Antioxidants (Basel) Date: 2020-03-07